最新ニュース Cybin (AMEX:CYBN) 株価情報

Cybin

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.

Cybin Inc

Cyber Security 1 AB ADR

Telsey Advisory Group analyst Dana Telsey maintains Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) with a Market Perform and maintains $6 price target.

News

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on Designer Brands, Maintains $6 Price Target

Morgan Stanley analyst Joseph Moore maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Underweight and lowers the price target from $112 to $81.

Morgan Stanley Maintains Underweight on Teradyne, Lowers Price Target to $81

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) with a Buy and maintains $10 price target.

Reiteration

RGLS

HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $10 Price Target

Telsey Advisory Group analyst Dana Telsey maintains G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) with a Market Perform and lowers the price target from $38 to $30.

GIII

Telsey Advisory Group Maintains Market Perform on G-III Apparel Group, Lowers Price Target to $30

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) with a Neutral and maintains $2 price target.

LYRA

HC Wainwright & Co. Reiterates Neutral on Lyra Therapeutics, Maintains $2 Price Target

Morgan Stanley analyst Kristine Liwag maintains StandardAero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SARO#NYSE">SARO</a>) with a Equal-Weight and lowers the price target from $33 to $32.

SARO

Morgan Stanley Maintains Equal-Weight on StandardAero, Lowers Price Target to $32

ETON

Eton Pharmaceuticals Announces Results From Bioequivalence Study Of ET-600 For Treatment Of Central Diabetes Insipidus; To Submit New Drug Application In April 2025

Buckle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKE#NYSE">BKE</a>) reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.44 by 6.25 percent. This is a 3.77 percent decrease over earnings of $1.59 per share from the same period last year. The company reported quarterly sales of $379.20 million which beat the analyst consensus estimate of $379.14 million by 0.02 percent. This is a 0.83 percent decrease over sales of $382.38 million the same period last year.

Earnings

Earnings Beats

Buckle Q4 EPS $1.53 Beats $1.44 Estimate, Sales $379.20M Beat $379.14M Estimate

The expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).&nbsp;
The approval also includes other updates to the label including to the Warnings and Precautions section.&nbsp;
As previously announced, the Company plans to market ILUVIEN for chronic NIU-PS in addition to its current indication of diabetic macular edema (DME) in the U.S. ILUVIEN is already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries.

ANIP

ANI Pharmaceuticals Says FDA Approved Expanded Label For ILUVIEN

Morgan Stanley analyst Simeon Gutman maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Overweight and lowers the price target from $500 to $460.

ULTA

Morgan Stanley Maintains Overweight on Ulta Beauty, Lowers Price Target to $460

HC Wainwright &amp; Co. analyst Yi Chen maintains Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) with a Buy and raises the price target from $49 to $50.

TRML

HC Wainwright & Co. Maintains Buy on Tourmaline Bio, Raises Price Target to $50

Crown Castle Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) shares surged premarket on Friday after the company disclosed a deal yesterday to sell all of its Fiber segment<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44316056/crown-castle-announces-agreement-to-sell-fiber-segment-to-eqt-and-zayo-reports-fourth-quarter-and-" rel="noreferrer noopener"> and announced quarterly results</a>.
Fiber Segment Asset Sale: The company inked a deal to sell its Fiber segment, including supporting assets and personnel, for $8.5 billion.
In particular, EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) will acquire the small cells business, while DigitalBridge Group, Inc.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBRG#NYSE">DBRG</a>) Zayo will take over the fiber solutions division.
Crown Castle plans to use the proceeds to repay debt and fund a $3.0 billion share repurchase program, aiming to maintain its investment-grade credit rating.
The company expects to reduce its annualized dividend to around $4.25 per share starting in the second quarter of FY25.
After the transaction closes, Crown Castle plans to set its annualized dividend at approximately 75% to 80% of AFFO, excluding amortization of prepaid rent.
Crown Castle expects to grow its annualized dividend in line with the growth in AFFO per share, excluding amortization of prepaid rent, following the transaction&#8217;s completion.
With this acquisition, Zayo expects to enhance its network by adding approximately 90,000 route miles of fiber, boosting its total reach <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44316602/digitalbridge-portfolio-company-zayo-to-acquire-crown-castles-fiber-solutions-business-in-4-25-bil" rel="noreferrer noopener">to over 70,000 on-net locations.</a>
Alexander Greenbaum, Partner and Head of EQT&#8217;s Active Core Infrastructure Advisory team, said, &#8220;This investment is a natural fit within EQT Active Core Infrastructure&#8217;s strategy &#8211; investing behind long-term contracted, core infrastructure <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44317066/eqt-to-acquire-crown-castles-small-cells-solutions-business" rel="noreferrer noopener">assets with strong growth potential.</a>&#8221;&nbsp;
The transaction is expected to close in the first half of 2026, pending regulatory approvals. As of December 31, 2024, EQT&#8217;s cash and cash <a href="https://www.benzinga.com/pressreleases/25/02/n43798363/eqt-reports-fourth-quarter-and-full-year-2024-results-and-provides-2025-guidance" target="_blank" rel="noreferrer noopener">equivalent stood at $202.1 million</a>.
Fourth Quarter&nbsp;Results: Crown Castle reported fourth-quarter FFO of $1.80, slightly missing the $1.81 estimate, while sales came in at $1.65 billion, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">exceeding the $1.64 billion estimate</a>.
Site rental revenue remained broadly flat year over year at $1.60 billion. Adjusted EBITDA declined slightly to $1.04 billion from $1.08 billion in prior year quarter.
As of December 31,&nbsp;2024, Crown Castle&#8217;s cash and cash equivalent stood at $295 million.
FY25 Outlook: Crown Castle expects AFFO <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">per share of $4.06 &#8211; $4.17</a>. The company sees site rental revenue of $3.987 billion &#8211; $4.032 billion, site rental billings of $3.885 billion &#8211; $3.915 billion and adjusted EBITDA of $2.755 billion &#8211; $2.805 billion.
Steven Moskowitz, Chief Executive Officer of Crown Castle, said, &#8221;In 2025, we expect a consistent level of activity with organic growth&nbsp;of 4.5% in towers, excluding the impact of Sprint consolidation churn, and anticipate lease and amendment applications to increase year-over-year as our customers continue to add capacity to their 5G networks to meet the persistent growth in mobile data demand in the U.S.&#8221;
Investors can gain exposure to the stock via iShares U.S. Digital Infrastructure and Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDGT#NYSE">IDGT</a>) and Global X Data Center &amp; Digital Infrastructure ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTCR#NASDAQ">DTCR</a>).
Price Action: CCI shares are up 6.24% at $101.02 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44302923/oracle-leverages-ai-to-automate-financial-crime-probes-boosting-efficiency" target="_blank" rel="noreferrer noopener">Oracle Leverages AI To Automate Financial Crime Probes, Boosting Efficiency</a></li>
</ul>
Photo via Shutterstock.

Equities

Large Cap

Asset Sales

Movers

DBRG

DTCR

iShares U.S. Digital Infrastructure and Real Estate ETF

IDGT

Why Is Crown Castle Stock Surging Today?

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) with a Buy and maintains $35 price target.

ATYR

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

On Thursday, March 13, U.S. markets ended notably lower, with the S&amp;P 500 entering <a target="_blank" href="https://www.benzinga.com/government/regulations/25/03/44317410/sp-500-enters-technical-correction-as-trade-war-fears-rattle-markets" rel="noreferrer noopener">correction</a> territory as escalating U.S. tariffs overshadowed encouraging inflation data.
Despite cooler-than-expected PPI and CPI readings and steady jobless claims suggesting inflation is easing, and the labor market remains strong, investor sentiment deteriorated. A broad selloff, led by losses in tech megacaps like the &#8220;Magnificent 7,&#8221; dragged major indexes down. Trade tensions flared as the EU retaliated against U.S. metal tariffs.
In economic data, U.S. producer prices were flat in February, missing expectations of a 0.3% rise after a revised 0.6% gain in January. Jobless claims fell by 2,000 to 220,000, below the forecast of 225,000.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/25/03/44301836/trump-warns-of-200-tariff-on-french-champagne-and-eu-spirits-in-retaliation-to-europes-tariff-on-us-whiskey" rel="noreferrer noopener">Trump Warns Of 200% Tariff On French Champagne And EU Spirits In Retaliation To Europe&#8217;s Tariff On US Whiskey</a>
Most S&amp;P 500 sectors fell Thursday, led by losses in consumer discretionary, real estate, and communication services, while utilities ended higher.
The Dow Jones Industrial Average fell 1.30% to close at 40,813.57, the S&amp;P 500 slid 1.39% to 5,521.52, and the Nasdaq Composite declined 1.96% to 17,303.01.
Asia Markets Today
<ul>
<li>On Friday, Japan&#8217;s Nikkei 225 rose 0.73% to 37,078.50, led by gains in the Power, Rubber and Chemical, Petroleum &amp; Plastic sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 was up 0.52% and closed at 7,789.70.</li>
<li>India markets closed for the Holi festival holiday.</li>
<li>China&#8217;s Shanghai Composite gained 1.81% to 3,419.56, and the Shanghai Shenzhen CSI 300 rose   2.43% to 4,006.56.</li>
<li>Hong Kong&#8217;s Hang Seng increased 2.12%, ending the session at 23,959.98.</li>
<li>Chinese stocks rallied on hopes of new economic stimulus, including possible PBOC liquidity measures and policies to boost consumption ahead of Monday&#8217;s press conference with top officials.</li>
</ul>
Eurozone at 05:45 AM ET
<ul>
<li>The European STOXX 50 was up 0.60%.</li>
<li>Germany&#8217;s DAX gained 0.55%.</li>
<li>France&#8217;s CAC rose 0.65%.</li>
<li>U.K.&#8217;s FTSE 100 index traded higher by 0.41%</li>
</ul>
Commodities at 05:45 AM ET
Crude Oil WTI was trading higher by 1.01% at $67.21/bbl, and Brent was up 0.90% at $70.51/bbl.
Oil prices rebounded Friday after prior losses, supported by fading hopes of a quick Ukraine ceasefire and potential cuts in Russian supply.
Natural Gas declined 0.63% to $4.085.
Gold was trading higher by 0.66% at $3,010.96, Silver was up 1.36% to $34.773, and Copper rose 0.04% to $4.9270.
Gold surged to a record high near $3,000 amid trade war fears and rate cut expectations. Strong haven demand, ETF inflows, and Fed policy outlook continue to boost sentiment.
U.S. Futures at 05:45 AM ET
Dow futures were up 0.54%, S&amp;P 500 futures rose 0.76% and Nasdaq 100 futures gained 1.00%.
Forex at 05:45 AM ET
The U.S. dollar index gained 0.08% to 103.92, the USD/JPY rose by 0.076% to 148.93, and the USD/AUD declined by 0.34% to 1.5860.
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Advance, Gold Hits $3,000 - Global Markets Today While US Slept

The Chemours Company Launches Full-Scale Product Trial For Data Center Two-Phase Immersion Cooling with NTT DATA And Hibiya Engineering, Utilizing Opteon 2P50 FluiW

B of A Securities analyst Tazeen Ahmad downgrades Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) from Buy to Underperform and lowers the price target from $11 to $1.

Downgrades

STRO

B of A Securities Downgrades Sutro Biopharma to Underperform, Lowers Price Target to $1

Needham analyst Ryan Koontz reiterates Kaltura (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTR#NASDAQ">KLTR</a>) with a Buy and maintains $3 price target.

KLTR

Needham Reiterates Buy on Kaltura, Maintains $3 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) with a Buy and maintains $37 price target.

PHAR

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright &amp; Co. analyst Sameer Joshi reiterates Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) with a Buy and maintains $8 price target.

BLNK

HC Wainwright & Co. Reiterates Buy on Blink Charging, Maintains $8 Price Target

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) with a Buy and maintains $7 price target.

HC Wainwright & Co. Reiterates Buy on Emeren Group, Maintains $7 Price Target

Press Releases

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Comments

Cybin

ニュース

最新ニュース Cybin (AMEX:CYBN) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル